GENGLYCOS

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
GENGLYCOS
Generic name
PARIGLASGENE BRECAPARVOVEC-OPNR
Manufacturer
Ultragenyx Pharmaceutical Inc.
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
ef9144f5-10c3-47d9-a7c6-ab5ff11e9bf8
SPL ID
84175036-1036-40bf-8134-df5deffa21ec
Version
4
Effective date
2026-08-28
Source export date
2026-11-13
Source partition
10
Source file
https://download.open.fda.gov/drug/label/drug-label-0010-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/829e43b83940afb8dda22d5287c5b17e57d3fe45d1157678854b4f9b7ad07271/drug-label-0010-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 17:15:15

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5. WARNINGS AND PRECAUTIONS Hypersensitivity and Infusion Reactions: Monitor during and after infusion. If symptoms occur, pause the infusion. Restart at half the prior rate after the infusion reaction has resolved. ( 2.4 , 5.1 ) Hepatotoxicity: Monitor transaminase levels and liver health for the first 6 months. Continue to monitor transaminases in all patients who develop liver enzyme elevations until liver enzymes return to baseline. ( 5.2 ) Adrenal Insufficiency: Monitor patients for signs and symptoms of adrenal insufficiency and adrenal crisis after GENGLYCOS administration during and after corticosteroid therapy and tapering. ( 5.3 ) AAV Vector Integration and Risk of Tumorigenicity: There is a theoretical risk of tumorigenicity due to integration of AAV vector DNA into the genome. Report cases of tumors in patients who received GENGLYCOS, to Ultragenyx Pharmaceutical. ( 5.4 ) 5.1. Hypersensitivity and Infusion Reactions Hypersensitivity reactions including anaphylaxis and infusion reactions (IRs) have occurred with GENGLYCOS treatment. Severe reactions have been reported [see Adverse Reactions (6.1) ]. Monitor for signs and symptoms of hypersensitivity and IRs, including urticaria, flushing, hypotension, bronchospasm, dyspnea, chest tightness, nausea, vomiting, headache, abdominal pain, lightheadedness, flu-like symptoms, shivering, rash, and hypertension. Premedicate with acetaminophen and non-sedating antihistamines and administer GENGLYCOS according to recommended infusion rates. Monitor patients during and after completion of GENGLYCOS infusion as clinically indicated. If anaphylaxis or a severe IR occurs, pause GENGLYCOS infusion immediately and initiate medical treatment as clinically indicated, monitoring as needed. For mild to moderate IRs, consider slowing or temporarily interrupting the infusion, and administer symptomatic treatment as clinically indicated. The infusion may be restarted at half the prior rate upon resolution of symptoms. [see Dosage and Administration (2.4) ] . Medical support measures, including cardiopulmonary resuscitation equipment and medications for the treatment of anaphylaxis (e.g., epinephrine, antihistamines, corticosteroids), should be available during GENGLYCOS administration. 5.2. Hepatotoxicity Immune-mediated hepatotoxicity, with elevated ALT and/or AST levels, has occurred with GENGLYCOS [see Adverse Reactions (6.1) ]. Avoid use in patients with preexisting hepatic impairment or acute hepatic viral infection. Prior to GENGLYCOS infusion, evaluate liver-related medical history and assess liver function by clinical examination and laboratory testing. Advise patients to immediately report signs and symptoms of hepatotoxicity, including fatigue, jaundice, dark urine, nausea, vomiting, and right upper quadrant pain. Administer corticosteroids to all patients after GENGLYCOS infusion in order to mitigate hepatic reactions. Elevated transaminases may require adjustment of the corticosteroid treatment regimen, including increased dose or prolongation of the corticosteroid taper [see Dosage and Administration (2.4) ] . Monitor transaminase levels for the first 6 months after GENGLYCOS administration. Continue to monitor transaminases in all patients who develop transaminase elevations, until transaminases return to baseline or as clinically indicated [see Dosage and Administration (2.4) ]. 5.3. Adrenal Insufficiency Adrenal insufficiency, including serious events, has been reported in patients receiving GENGLYCOS during corticosteroid use and tapering. [see Adverse Reactions (6.1) ]. Signs and symptoms of adrenal insufficiency include fatigue, weakness, anorexia, nausea, vomiting, hypotension, hyponatremia, and hypoglycemia. Adrenal crisis may present as severe hypotension, acute abdominal pain, or loss of consciousness. Monitor patients for signs and symptoms of adrenal insufficiency and adrenal crisis after GENGLYCOS administration during and after corticosteroid therapy and tapering. [see Dosage and Administration (2.4) ]. Taper corticosteroid therapy gradually. Do not abruptly discontinue corticosteroid therapy. 5.4. AAV Vector Integration and Risk of Tumorigenicity There is a theoretical risk of tumorigenicity due to integration of AAV vector DNA into the genome. GENGLYCOS is composed of a recombinant, non-replicating AAV8 vector whose DNA persists largely in episomal form. Random integration of recombinant AAV-vector DNA into human DNA has been reported with AAV gene therapies. The clinical relevance of individual integration events is unknown, but it is acknowledged that individual integration events could potentially contribute to a risk of tumorigenicity. If a tumor develops in a patient receiving GENGLYCOS, health care providers should contact and report the tumor to Ultragenyx Pharmaceutical Inc. at 1-888-756-8657.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6. ADVERSE REACTIONS Most common adverse reactions (incidence ≥10%) are increased transaminases and nausea. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Ultragenyx Pharmaceutical Inc. at 1-888-756-8657 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1. Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety data described in this section reflects exposure to GENGLYCOS in two clinical studies. Study 1 was a randomized, double-blind, placebo-controlled study in 46 patients aged 8 years and older with GSDIa. During the Primary Efficacy Analysis Period (PEAP, Weeks 1–48), 21 patients received GENGLYCOS at the recommended dose of 1.0 × 10¹³ gc/kg and 25 received placebo. After Week 48, 19 placebo-treated patients subsequently received GENGLYCOS up to Week 96. Study 2 was a single-arm, open-label study of GENGLYCOS in 12 adults with GSDIa with follow up duration of 52 weeks. Seven serious adverse events (SAEs) were observed in PEAP of Study 1, including anaphylaxis /infusion reaction (2), adrenal insufficiency (2), high lactate level (2), and hypoglycemia (1). The most common adverse reactions in the PEAP (occurring in ≥10 % of patients) with higher frequency in GENGLYCOS compared to placebo during PEAP in Study 1 are shown in Table 4. Table 4: Adverse Reactions: Study 1 Preferred Term GENGLYCOS (N=21) Events n | Subjects N (%) Placebo (N=25) Events n | Subjects N (%) Abbreviations: ALT: Alanine Aminotransferase; AST: Aspartate Aminotransferase. ALT/AST Enzyme elevated All events were mild to moderate (< 5.0× ULN), except one severe (Grade 3) asymptomatic event (peak ALT: 253 U/L). ALT/AST elevations peaked between 4 and 12 weeks post-GENGLYCOS administration and resolved within 15 weeks [see Warnings and Precautions (5.2) ] 29 | 15 (71) 6 | 3 (12) Nausea 12 | 8 (38) 10 | 4 (16) Headache 11 | 5 (24) 9 | 3 (12) Hypertriglyceridemia All adverse events were mild to moderate. 10 | 6 (29) 2 | 2 (8) Adrenal Insufficiency Two SAEs were reported [see Warnings and Precautions (5.3) ]. 7 | 5 (24) 0 | 0 Constipation 5 | 4 (19) 0 | 0 Hyperglycemia All adverse events were mild. 5 | 3 (14) 0 | 0 Acne / Dermatitis Acneiform 4 | 4 (19) 0 | 0 Cushingoid Features 3 | 3 (14) 0 | 0 Anaphylaxis Two Serious adverse reactions with onset within minutes of GENGLYCOS administration [see Warnings and Precautions (5.1) ] 2 | 2 (10) 0 | 0 Safety evaluations during the Crossover Period of Study 1 and in Study 2 did not identify any additional adverse reactions.

adverse reactions table

<table width="80%"> <caption>Table 4: Adverse Reactions: Study 1</caption> <col width="34%" align="left" valign="middle"/> <col width="33%" align="left" valign="middle"/> <col width="33%" align="left" valign="middle"/> <thead> <tr> <th styleCode="Lrule Rrule">Preferred Term</th> <th styleCode="Rrule">GENGLYCOS (N=21) Events n | Subjects N (%)</th> <th styleCode="Rrule">Placebo (N=25) Events n | Subjects N (%)</th> </tr> </thead> <tfoot> <tr> <td align="left" colspan="3">Abbreviations: ALT: Alanine Aminotransferase; AST: Aspartate Aminotransferase.</td> </tr> </tfoot> <tbody> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">ALT/AST Enzyme elevated<footnote>All events were mild to moderate (&lt; 5.0&#xD7; ULN), except one severe (Grade 3) asymptomatic event (peak ALT: 253 U/L). ALT/AST elevations peaked between 4 and 12 weeks post-GENGLYCOS administration and resolved within 15 weeks [see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</footnote> </td> <td styleCode="Rrule">29 | 15 (71)</td> <td styleCode="Rrule">6 | 3 (12)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Nausea</td> <td styleCode="Rrule">12 | 8 (38)</td> <td styleCode="Rrule">10 | 4 (16)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Headache</td> <td styleCode="Rrule">11 | 5 (24)</td> <td styleCode="Rrule">9 | 3 (12)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Hypertriglyceridemia<footnote>All adverse events were mild to moderate.</footnote> </td> <td styleCode="Rrule">10 | 6 (29)</td> <td styleCode="Rrule">2 | 2 (8)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Adrenal Insufficiency<footnote>Two SAEs were reported [see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>].</footnote> </td> <td styleCode="Rrule">7 | 5 (24)</td> <td styleCode="Rrule">0 | 0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Constipation</td> <td styleCode="Rrule">5 | 4 (19)</td> <td styleCode="Rrule">0 | 0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Hyperglycemia<footnote>All adverse events were mild.</footnote> </td> <td styleCode="Rrule">5 | 3 (14)</td> <td styleCode="Rrule">0 | 0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Acne / Dermatitis Acneiform</td> <td styleCode="Rrule">4 | 4 (19)</td> <td styleCode="Rrule">0 | 0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Cushingoid Features</td> <td styleCode="Rrule">3 | 3 (14)</td> <td styleCode="Rrule">0 | 0</td> </tr> <tr> <td styleCode="Lrule Rrule">Anaphylaxis<footnote>Two Serious adverse reactions with onset within minutes of GENGLYCOS administration [see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</footnote> </td> <td styleCode="Rrule">2 | 2 (10)</td> <td styleCode="Rrule">0 | 0</td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.